Researchers at the Cancer Research UK-AstraZeneca Antibody Alliance Laboratory in Cambridge, UK, have developed a new technique able to generate an inhibitory, high-affinity antibody against Arginase 2 (ARG2), an enzyme implicated in major human diseases.